Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Total Voting Rights

28 Feb 2012 08:00

RNS Number : 2470Y
Angle PLC
28 February 2012
 



For immediate release

28 February 2012

 

ANGLE plc

("ANGLE" or the "Company")

 

Issue of Equity and Total Voting Rights

 

ANGLE plc, which focuses on the commercialisation of technology, is pleased to announce that it has now received Advanced Assurance from HMRC of eligibility for EIS and VCT relief in relation to the new ordinary shares of 10 pence each (the "Fundraising Shares") to be issued pursuant to the fundraising announced on 26 January 2012. As a result, the Company has applied for the Fundraising Shares to be admitted to trading on AIM. Admission of the Fundraising Shares to trading on AIM is expected as to 1,187,145 Ordinary shares at 8.00am on 2 March 2012 for the EIS and VCT qualifying investors and as to 528,572 Ordinary shares at 8.00am on 5 March 2012 for the other investors ("Admission").

For the purposes of the Financial Services Authority's Disclosure and Transparency Rules, the Company's total issued share capital following Admission will consist of 37,824,559 Ordinary Shares of 10 pence each, with one voting right per share. There are no shares held in treasury.

The total number of voting rights in the Company will therefore be 37,824,559.

The above figure of 37,824,559 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest, in the Company, under the Disclosure and Transparency Rules.

 

For further information:

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Cenkos Securities

Stephen Keys, Adrian Hargrave (Nominated Adviser)

Andy Roberts (Sales)

 

020 7397 8900

 

 

Buchanan

Mark Court, Sophie Cowles

 

020 7466 5000

Scott Harris

Stephen Scott, Harry Dee

 

020 7653 0030

 

 

ANGLE is quoted on AIM (AGL.L); further information can be found on www.ANGLEplc.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVRPGUCWPUPPUMR
Date   Source Headline
29th Oct 20257:00 amRNS-RCHANGE OF NAME
16th Oct 20257:00 amRNSAppointments: Interim CEO and senior board advisor
8th Oct 20257:00 amRNSStrategy Update
29th Sep 20257:00 amRNS-RPresentation of Data on Glioblastoma
12th Sep 20257:00 amRNSBoard Changes
9th Sep 20257:01 amRNSInterim Results
9th Sep 20257:00 amRNSChange of Adviser
5th Sep 20252:58 pmRNSNotice of Results
20th Aug 20257:00 amRNSANGLE announces collaboration with Myriad Genetics
8th Jul 20257:00 amRNS-RPARSORTIX ENABLES STUDY OF CANCER PROGRESSION
30th Jun 20255:50 pmRNSResult of 2025 Annual General Meeting
17th Jun 20257:00 amRNS-REACR 2025: Innovation in AR expression profiling
17th Jun 20257:00 amRNS-REACR 2025: Data demonstrating DNA dual analysis
10th Jun 20257:00 amRNS-RNovel discoveries into the biology of cancer
9th Jun 20257:00 amRNSPOSTING OF ANNUAL REPORT AND NOTICE OF AGM
6th Jun 20257:00 amRNSBoard Changes
28th May 20257:00 amRNSPreliminary Results
23rd May 20257:00 amRNSNotice of Results
28th Apr 20257:00 amRNS-RRESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME
21st Mar 20257:00 amRNSIssue of LTIP Options and Share Options
21st Mar 20257:00 amRNSResults of Eisai Phase 2 pilot study
6th Feb 20257:00 amRNS-RNovel findings using Parsortix
29th Jan 20257:00 amRNSAnalysis of CTC-DNA and ctDNA using Illumina assay
24th Jan 202510:05 amRNS-RParsortix used in research paper from ETH Zurich
23rd Jan 20257:00 amRNSTrading Update
26th Sep 20247:00 amRNSHalf-year Report
23rd Sep 20247:00 amRNSExclusive agreement for DNA NGS panel
17th Sep 20247:00 amRNSNotice of Interim Results and Webcast
18th Jul 202410:08 amRNSStandard form for notification of major holdings
12th Jul 20243:38 pmRNSStandard form for notification of major holdings
11th Jul 20243:07 pmRNSResult of 2024 Annual General Meeting
21st Jun 20247:00 amRNSResult of open offer
18th Jun 20242:41 pmRNSPosting of 2023 Annual Report & Notice of the AGM
11th Jun 20247:00 amRNSParsortix and assays being showcased at EACR 2024
6th Jun 20244:37 pmRNSPublication of Circular
5th Jun 20244:04 pmRNSResults of placing and subscription
5th Jun 20247:00 amRNSProposed Placing, Subscription and Open Offer
5th Jun 20247:00 amRNSPreliminary Results
16th May 20247:00 amRNSStudy of ovarian cancer CTCs using Parsortix
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.